Literature DB >> 21085094

Oral administration of rotenone using a gavage and image analysis of alpha-synuclein inclusions in the enteric nervous system.

Francisco J Pan-Montojo1, Richard H W Funk.   

Abstract

In Parkinson's disease (PD) patients, the associated pathology follows a characteristic pattern involving inter alia the enteric nervous system (ENS) (1,2), the olfactory bulb (OB), the dorsal motor nucleus of the vagus (DMV)(3), the intermediolateral nucleus of the spinal cord (4) and the substantia nigra, providing the basis for the neuropathological staging of the disease(4,5). The ENS and the OB are the most exposed nervous structures and the first ones to be affected. Interestingly, PD has been related to pesticide exposure(6-8). Here we show in detail two methods used in our previous study (9). In order to analyze the effects of rotenone acting locally on the ENS, we administered rotenone using a gavage to one-year old C57/BL6 mice. Rotenone is a widely used pesticide that strongly inhibits mitochondrial Complex I (10). It is highly lipophylic and poorly absorbed in the gastrointestinal tract (11). Our results showed that the administration of 5 mg/kg of rotenone did not inhibit mitochondrial Complex I activity in the muscle or the brain. Thus, suggesting that using our administration method rotenone did not cross the hepatoportal system and was acting solely on the ENS. Here we show a method to administer pesticides using a gavage and the image analysis protocol used to analyze the effects of the pesticide in alpha-synuclein accumulation in the ENS. The first part shows a method that allows intragastric administration of pesticides (rotenone) at a desired precise concentration. The second method shows a semi-automatic image analysis protocol to analyze alpha-synuclein accumulation in the ENS using an image analysis software.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21085094      PMCID: PMC3280635          DOI: 10.3791/2123

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  12 in total

1.  Restricted occurrence of Lewy bodies in the dorsal vagal nucleus in a patient with late-onset parkinsonism.

Authors:  K Wakabayashi; Y Toyoshima; K Awamori; T Anezaki; M Yoshimoto; S Tsuji; H Takahashi
Journal:  J Neurol Sci       Date:  1999-06-01       Impact factor: 3.181

2.  Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology.

Authors:  Heiko Braak; Rob A I de Vos; Jürgen Bohl; Kelly Del Tredici
Journal:  Neurosci Lett       Date:  2005-12-05       Impact factor: 3.046

3.  Parkinson's disease and exposure to agricultural work and pesticide chemicals.

Authors:  K M Semchuk; E J Love; R G Lee
Journal:  Neurology       Date:  1992-07       Impact factor: 9.910

Review 4.  Toxin-induced models of Parkinson's disease.

Authors:  Jordi Bové; Delphine Prou; Céline Perier; Serge Przedborski
Journal:  NeuroRx       Date:  2005-07

5.  Parkinson's disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons.

Authors:  Heiko Braak; Magdalena Sastre; Jürgen R E Bohl; Rob A I de Vos; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2007-02-09       Impact factor: 17.088

Review 6.  Stages in the development of Parkinson's disease-related pathology.

Authors:  Heiko Braak; Estifanos Ghebremedhin; Udo Rüb; Hansjürgen Bratzke; Kelly Del Tredici
Journal:  Cell Tissue Res       Date:  2004-08-24       Impact factor: 5.249

7.  Environmental antecedents of young-onset Parkinson's disease.

Authors:  P G Butterfield; B G Valanis; P S Spencer; C A Lindeman; J G Nutt
Journal:  Neurology       Date:  1993-06       Impact factor: 9.910

8.  Parkinson's disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system.

Authors:  K Wakabayashi; H Takahashi; E Ohama; F Ikuta
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

9.  Mechanism of toxicity in rotenone models of Parkinson's disease.

Authors:  Todd B Sherer; Ranjita Betarbet; Claudia M Testa; Byoung Boo Seo; Jason R Richardson; Jin Ho Kim; Gary W Miller; Takao Yagi; Akemi Matsuno-Yagi; J Timothy Greenamyre
Journal:  J Neurosci       Date:  2003-11-26       Impact factor: 6.167

10.  Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice.

Authors:  Francisco Pan-Montojo; Oleg Anichtchik; Yanina Dening; Lilla Knels; Stefan Pursche; Roland Jung; Sandra Jackson; Gabriele Gille; Maria Grazia Spillantini; Heinz Reichmann; Richard H W Funk
Journal:  PLoS One       Date:  2010-01-19       Impact factor: 3.240

View more
  11 in total

Review 1.  Neuropathobiology of non-motor symptoms in Parkinson disease.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2015-05-15       Impact factor: 3.575

Review 2.  Agrochemicals, α-synuclein, and Parkinson's disease.

Authors:  Blanca A Silva; Leonid Breydo; Anthony L Fink; Vladimir N Uversky
Journal:  Mol Neurobiol       Date:  2012-08-30       Impact factor: 5.590

Review 3.  Neurophysiology of the brain stem in Parkinson's disease.

Authors:  Cecilia Bove; R Alberto Travagli
Journal:  J Neurophysiol       Date:  2019-03-27       Impact factor: 2.714

4.  Characterization of the Basic Membrane Properties of Neurons of the Rat Dorsal Motor Nucleus of the Vagus in Paraquat-Induced Models of Parkinsonism.

Authors:  C Bove; F H Coleman; R A Travagli
Journal:  Neuroscience       Date:  2019-09-03       Impact factor: 3.590

Review 5.  Classic and new animal models of Parkinson's disease.

Authors:  Javier Blesa; Sudarshan Phani; Vernice Jackson-Lewis; Serge Przedborski
Journal:  J Biomed Biotechnol       Date:  2012-03-28

6.  Changes in the sympathetic innervation of the gut in rotenone treated mice as possible early biomarker for Parkinson's disease.

Authors:  Mike Arnhold; Yanina Dening; Michaël Chopin; Esteban Arévalo; Mathias Schwarz; Heinz Reichmann; Gabriele Gille; Richard H W Funk; Francisco Pan-Montojo
Journal:  Clin Auton Res       Date:  2016-05-13       Impact factor: 4.435

7.  Combined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson's disease.

Authors:  Hui-Fang Liu; Philip Wing-Lok Ho; Gideon Chi-Ting Leung; Colin Siu-Chi Lam; Shirley Yin-Yu Pang; Lingfei Li; Michelle Hiu-Wai Kung; David Boyer Ramsden; Shu-Leong Ho
Journal:  Sci Rep       Date:  2017-01-18       Impact factor: 4.379

8.  NF-κB/c-Rel deficiency causes Parkinson's disease-like prodromal symptoms and progressive pathology in mice.

Authors:  Edoardo Parrella; Arianna Bellucci; Vanessa Porrini; Marina Benarese; Annamaria Lanzillotta; Gaia Faustini; Francesca Longhena; Giulia Abate; Daniela Uberti; Marina Pizzi
Journal:  Transl Neurodegener       Date:  2019-05-21       Impact factor: 8.014

Review 9.  Mitochondrial Dysfunction and α-Synuclein Synaptic Pathology in Parkinson's Disease: Who's on First?

Authors:  Michela Zaltieri; Francesca Longhena; Marina Pizzi; Cristina Missale; PierFranco Spano; Arianna Bellucci
Journal:  Parkinsons Dis       Date:  2015-03-31

Review 10.  Research on the premotor symptoms of Parkinson's disease: clinical and etiological implications.

Authors:  Honglei Chen; Edward A Burton; G Webster Ross; Xuemei Huang; Rodolfo Savica; Robert D Abbott; Alberto Ascherio; John N Caviness; Xiang Gao; Kimberly A Gray; Jau-Shyong Hong; Freya Kamel; Danna Jennings; Annette Kirshner; Cindy Lawler; Rui Liu; Gary W Miller; Robert Nussbaum; Shyamal D Peddada; Amy Comstock Rick; Beate Ritz; Andrew D Siderowf; Caroline M Tanner; Alexander I Tröster; Jing Zhang
Journal:  Environ Health Perspect       Date:  2013-08-09       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.